Caribou Biosciences, Inc. (CRBU) · Nov 5, 2026 · Earnings

Caribou earnings show smaller loss as shutdown story holds

In line — Net loss $26.6M vs $27.5M prior year; no new operating plan

Caribou’s earnings show a slightly smaller quarterly loss and lower expenses, but the October decision to halt its CAR-T pipeline still defines the business.

Caribou is no longer operating as a normal clinical-stage biotech: after previously funding vispa-cel and CB-011 toward pivotal development, it announced on October 6, 2026 that it would stop both programs, cut its workforce, and pursue strategic alternatives. Its prior second-quarter plan had contemplated funding selected development work through the end of 2027, but that operating strategy was overtaken by the restructuring announcement.

The quarter’s financial update is mostly housekeeping after the strategic reset. Revenue fell to $1.6 million from $2.2 million a year earlier, while the net loss narrowed only modestly to $26.6 million from $27.5 million.

Q3 2026Q3 2025Year-end 2025
Licensing revenue (Financial Highlights)$1.6M (-26.9%)$2.2M
Net loss (Financial Highlights)$26.6M (-3.4%)$27.5M
Diluted loss per share (Financial Highlights)$0.25$0.30
Cash and marketable securities (Balance Sheet)$94.8M$142.8M

Cost control is visible, but it does not revive the operating story. Research and development and general and administrative spending both declined year over year, consistent with the workforce reduction and pipeline shutdown. That helped narrow the loss, but cash and marketable securities fell to $94.8 million from $142.8 million at December 31, 2025.

The genuinely important news was already public. The filing repeats that Caribou is discontinuing further development of vispa-cel and CB-011 while exploring a merger, acquisition, business combination, asset transaction, or possible liquidation. 〔0〕 The company provides no timetable or new transaction detail, so this earnings release does not materially change the post-shutdown situation.

Bottom line: The numbers show modest expense discipline but continued cash depletion and shrinking revenue. Because the pipeline halt and strategic review were already disclosed, this filing is routine confirmation rather than a new change to Caribou’s business story.

What to watch next

Strategic alternatives review outcome

Original filing on SEC EDGAR

Caribou earnings show smaller loss as shutdown story holds | CRBU Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.